177Lu-DFC413

N/A

Report date: 2026/04/29 20:02:18

NME

Base Information

Drug Name177Lu-DFC413

Drug Alias Name177Lu-DFC413

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaSingaporeDenmark +[6]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A